ImmuCell Corporation ICCC

ICCC Company Overview

ImmuCell Corporation (NASDAQ: ICCC) is a U.S.-based animal health company focused on developing, manufacturing, and marketing products that improve the health and productivity of dairy and beef cattle. The company operates within the veterinary biologics and animal health industries, with a primary emphasis on disease prevention and treatment solutions for the dairy sector. Its core revenue drivers are commercially marketed products for calf health and mastitis treatment, particularly products designed to reduce antibiotic use and improve herd productivity.

The company’s flagship commercial product is First Defense®, an orally administered antibody product designed to help prevent scours in newborn calves caused by pathogens such as E. coli, coronavirus, and rotavirus. ImmuCell has also invested heavily in the development of Re-Tain®, a novel non-antibiotic treatment for subclinical mastitis in dairy cows. Founded in 1982 and headquartered in Portland, Maine, the company evolved from a biotechnology-focused research enterprise into a specialized animal health manufacturer targeting unmet needs in dairy production systems. Its strategic positioning centers on non-antibiotic health solutions and biologically derived products for livestock producers.